Related references
Note: Only part of the references are listed.Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer
Claire Biot et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response
Romulus Breban et al.
ONCOIMMUNOLOGY (2012)
A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer
Svetlana Bunimovich-Mendrazitsky et al.
JOURNAL OF THEORETICAL BIOLOGY (2011)
USE OF QUASI-NORMAL FORM TO EXAMINE STABILITY OF TUMOR-FREE EQUILIBRIUM IN A MATHEMATICAL MODEL OF BCG TREATMENT OF BLADDER CANCER
Svetlana Bunimovich-Mendrazitsky et al.
MATHEMATICAL BIOSCIENCES AND ENGINEERING (2011)
Cell-Mediated Immune Responses in Tuberculosis
Andrea M. Cooper
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder Cancer
Aurelie Bisiaux et al.
JOURNAL OF UROLOGY (2009)
Mathematical model of pulsed immunotherapy for superficial bladder cancer
Svetlana Bunimovich-Mendrazitsky et al.
BULLETIN OF MATHEMATICAL BIOLOGY (2008)
Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice
Beatrice Breart et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
The safety and efficacy of different doses of bacillus Calmette Guerin in superficial bladder transitional cell carcinoma
Madhu S. Agrawal et al.
UROLOGY (2007)
Mathematical model of BCG immunotherapy in superficial bladder cancer
Svetlana Bunimovich-Mendrazitsky et al.
BULLETIN OF MATHEMATICAL BIOLOGY (2007)
Efficient step size selection for the tau-leaping simulation method
Y Cao et al.
JOURNAL OF CHEMICAL PHYSICS (2006)
Intravesical bacillus Calmette-Guerin therapy:: experience with a reduced dwell-time in patients with pronounced side-effects
P Andius et al.
BJU INTERNATIONAL (2005)
BCG dose reduction by decreasing the instillation frequency: Effects on local Th1/Th2 cytokine responses in a mouse model
EC de Boer et al.
EUROPEAN UROLOGY (2005)
Maintenance bacillus Calmette-Guerin for TaT1 bladder tumors is not associated with increased toxicity: Results from a European organisation for research and treatment of cancer genito-urinary group phase III trial
APM van der Meijden et al.
EUROPEAN UROLOGY (2003)
Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer
JA Martínez-Piñeiro et al.
BJU INTERNATIONAL (2002)
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study
DL Lamm et al.
JOURNAL OF UROLOGY (2000)
Modified induction course: A solution to side-effects?
P Bassi et al.
EUROPEAN UROLOGY (2000)
Share Paper
